Clinical Trials in Nîmes, France
246 recruiting
Showing 1–20 of 274 trials
Recruiting
Phase 4
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Supraflex Stent Implantation
Atrial Fibrillation (AF)Percutaneous Coronary Intervention (PCI)Oral Anticoagulation+1 more
Insel Gruppe AG, University Hospital Bern3,010 enrolled15 locationsNCT05955365
Recruiting
Phase 3
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Breast Cancer (Early Breast Cancer)
AstraZeneca4,300 enrolled711 locationsNCT05774951
Recruiting
Phase 2Phase 3
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Janssen Research & Development, LLC201 enrolled113 locationsNCT05327114
Recruiting
Phase 2
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
HIV Infections
ViiV Healthcare150 enrolled113 locationsNCT07202546
Recruiting
Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Not Applicable
The PERSEVERE Study
Pulmonary EmbolismPulmonary Thromboembolism
Inari Medical200 enrolled26 locationsNCT06588634
Recruiting
Phase 3
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Intermediate Risk Non-Muscle Invasive Bladder Cancer
Ferring Pharmaceuticals454 enrolled94 locationsNCT06510374
Recruiting
Phase 3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
Prostate CancerProstatic Neoplasms
Merck Sharp & Dohme LLC1,440 enrolled282 locationsNCT06925737
Recruiting
Phase 3
A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
Ferring Pharmaceuticals250 enrolled73 locationsNCT06545955
Recruiting
Phase 2
Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
Clostridioides Difficile Infection
AstraZeneca230 enrolled114 locationsNCT07285213
Recruiting
Phase 3
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
Prostate Cancer Metastatic
Merck Sharp & Dohme LLC1,310 enrolled282 locationsNCT06136624
Recruiting
Phase 3
Aspirin for the Prevention of Preeclampsia and Pregnancy Outcomes After Assisted Reproductive Technology
Pre-EclampsiaART
University Hospital, Toulouse1,164 enrolled21 locationsNCT05625724
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
Moderately to Severely Active Ulcerative Colitis
Hoffmann-La Roche350 enrolled199 locationsNCT06588855
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled164 locationsNCT07225504
Recruiting
Phase 2Phase 3
Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis
End-stage Kidney DiseaseAtherosclerotic Cardiovascular DiseaseAtherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring2,310 enrolled542 locationsNCT05485961
Recruiting
Phase 3
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer
AstraZeneca880 enrolled301 locationsNCT06692738
Recruiting
Phase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
Merck Sharp & Dohme LLC600 enrolled216 locationsNCT06345729
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Crohn's Disease
Merck Sharp & Dohme LLC1,200 enrolled499 locationsNCT06430801
Recruiting
Autophagy/Apoptosis Balance in Placental Vascular Pathologies
Pregnancy ComplicationsPre-EclampsiaGrowth Retardation, Intrauterine
Centre Hospitalier Universitaire de Nīmes50 enrolled1 locationNCT06779916
Recruiting
Phase 1Phase 2
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
Myelofibrosis
Sumitomo Pharma America, Inc.240 enrolled84 locationsNCT04176198